Pretherapeutic Tumor Growth Velocity Refines Survival Stratification Beyond Clinical, Molecular, and Surgical Factors in IDH-Mutant Lower-Grade Gliomas

Clicks: 3
ID: 338754
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #289 of 289 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 289 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Contemporary risk stratification of isocitrate dehydrogenase (IDH)-mutant lower-grade gliomas relies primarily on molecular characteristics and surgical tumor burden but does not capture dynamic tumor behavior. Our primary objective was to determine whether pretherapeutic tumor growth velocity (TGV) provides independent prognostic information for overall survival (OS) beyond established factors. METHODS: This multicenter retrospective study included 569 adults with grade 2-3 IDH-mutant gliomas from three French centers, comprising a development cohort (n = 440) and two external validation cohorts (n = 129). TGV was derived from automated, outcome-blinded volumetric analysis of serial preoperative MRI using mean diameter expansion and log-volume growth. Prognostic value was assessed using multivariable Cox regression, external validation, decision curve analysis, and exploratory random survival forests. RESULTS: During a median follow-up of 6.8 years, 73 deaths occurred in the development cohort. Higher TGV was independently associated with shorter overall survival after adjustment for age, sex, grade, 1p/19q status, and postoperative residual tumor volume (HR per 1-mm/year increase, 1.046; 95%CI, 1.011-1.083; P=.011), and was independently replicated externally (HR, 1.077; 95% CI, 1.005-1.153; P=.035). Findings were consistent using log-volume growth and after accounting for CDKN2A/B status. Adding TGV improved prognostic model fit (likelihood-ratio χ²=5.70; P=.017), with greatest incremental value in astrocytomas. Decision curve analysis demonstrated additional clinical utility, while survival forests identified TGV among the strongest survival predictors alongside 1p/19q status and postoperative residual tumor volume. CONCLUSIONS: Pretherapeutic TGV independently predicts survival beyond contemporary molecular and surgical factors in IDH-mutant lower-grade gliomas. This accessible MRI-derived biomarker may refine individualized risk stratification, particularly in astrocytoma.
Reference Key
openalex_W7225244528 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sam Ng, Fabien Almairac, Jérémy Deverdun, Amélie Darlix, Lydiane Mondot, Elisabeth Fabre, Suzanne Tran, Guillaume Herbet, Valérie Rigau, Emmanuelle Le Bars, Emmanuel Mandonnet, Hugues Duffau
Are you one of these authors? Claim your profile
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag277
URL
https://doi.org/10.1093/neuonc/noag277
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.